Pancreatic Cancer Research

Clinical trialObservationalCompleted

Surgery for Pancreatic Cancer With Oligo-Metastasis

Surgery/Destruction for Stage IV Pancreatic Cancer With Oligo-Metastatic Disease

Outcome
Finished, no results posted
Phase
Observational
Status
Completed
Study type
Observational
Start
1 January 2020
Ended
1 December 2020
Enrollment
200 participants
Sites
1
Primary outcomes
Overall survival
Sponsor type
Academic / other
Results posted
No
Last update
29 December 2020

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Pancreatic cancer is increasing in incidence and will be the second leading cause of cancer-related deaths in 2030 in the West. Only 10 to 15% of patients are eligible for curative resection with long-term survival rarely exceeding 20% at 5 years. The management of metastatic or recurrent diseases can not, unfortunately, be recommended to date because of limited data available (INCA 2019). However, recent, low-strength publications have reported encouraging results on the long-term survival of stage IV or recurrent patients. The aim of the present retrospective cohort study is to analyze results of surgery/destruction of metastatic synchronous or metachronous disease or local recurrence in patients with stage IV pancreatic cancer